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Abstract
Background: In South Africa, HPV vaccination programme has been incorporated recently in the school health system. Since 
doctors are the most trusted people regarding health issues in general, their knowledge and attitudes regarding HPV infections 
and vaccination are very important for HPV vaccine program nationally. 
Objective: The objective of  this study was to investigate factors contributing to recommendation of  HPV vaccines to the pa-
tients. 
Methods: This was a quantitative cross-sectional study conducted among 320 doctors, using a self-administered anonymous 
questionnaire. 
Results: All the doctors were aware of  HPV and knew that HPV is transmitted sexually. Their overall level of  knowledge re-
garding HPV infections and HPV vaccine was poor. But the majority intended to prescribe the vaccine to their patients. It was 
found that doctors who knew that HPV 6 and 11 are responsible for >90% of  anogenital warts, their patients would comply 
with the counselling regarding HPV vaccination, and received sufficient information about HPV vaccination were 5.68, 4.91 and 
4.46 times respectively more likely to recommend HPV vaccination to their patients, compared to their counterparts (p<0.05). 
Conclusion: There was a knowledge gap regarding HPV infection and HPV vaccine among the doctors. 
Keywords: Human Papillomavirus vaccine, South Africa.
DOI: http://dx.doi.org/10.4314/ahs.v16i2.26
Cite as: Hoque ME. Factors influencing the recommendation of  the Human Papillomavirus vaccine by South African doctors working 
in a tertiary hospital. Afri Health Sci 2016;16(2): 567-575. http://dx.doi.org/10.4314/ahs.v16i2.26
Introduction
Cervical cancer is a serious public health problem among 
women of  reproductive age – even though it is pre-
ventable. It is the fourth most common cancer, and ap-
proximately 530,000 new cases and 275,000 deaths oc-
cur every year worldwide. Globally it is the second most 
common female cancer among women aged 15 to 44 
years.1 In South Africa, it is estimated that 7,735 women 
are diagnosed with cervical cancer, and 4,248 die from 
the disease annually. Cervical cancer is the most common 
cancer among women aged 15 to 44 years, and the most 
common cancer among women in South Africa.2 Even 
though cervical cancer screening for women 30 years or 
older is free, the coverage is very low as 13.6%.2
It is known that cervical cancer is caused by persistent 
Human Papillomavirus (HPV) infection. There are many 
types of  HPV, but HPV 16 and 18 are the main geno-
types, as 70% of  cervical cancers are caused by them and 
they are known as high-risk types. HPV 6 and 11 causes 
90% of  genital warts and are known as low-risk HPV.2 
At any given time in South Africa, about 3.2% of  women 
in the general population are harbouring HPV-16 or 18 
infection, and about 64% of  invasive cervical cancers are 
attributed to HPV types 16 or 18.2
There are two prophylactic HPV vaccines: quadrivalent 
and bivalent. Quadrivalent vaccine targets HPV types 6, 
11, 16 and 18, and a bivalent vaccine targets types 16 and 
18. Both vaccines are commercially available. More than 
100 countries in the world have been licensed to use one 
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or both vaccines, and many countries have incorporated 
HPV vaccine into their routine vaccination programme.3 
Many well-designed clinical trial studies conducted among 
15 to 45 year-old women to investigate the safety and ef-
ficacy of  the vaccines, have found that both vaccines had 
high efficacy and are safe.4-8 But there are still certain con-
troversies about ethical issues, the long-term effects and 
complications.9-11 Another HPV vaccine named 9-valent 
has been developed by including HPV types 31, 33, 45, 
52 and 58 to the quadrivalent vaccine.12 This nonavalent 
(9-valent) vaccine is currently under regulatory assess-
ment for possible marketing authorization.
In the beginning, the HPV vaccines were licensed for fe-
males aged 9 to 26 years – to be given in three doses.13 
These vaccines work best if  administered before becom-
ing sexually active. It has been shown that the vaccine’s 
immunity lasts about seven years if  the women concerned 
were not infected at the time of  vaccination.14-16 Because 
of  this, many countries recommend the administration 
of  the vaccine to girls aged 11 to 14 years.8,17,18 According 
to WHO, the recommended age group for HPV vacci-
nation is girls aged 9 to 13 years – as the primary target 
population.12 Vaccination of  older adolescent females or 
young women is recommended only if  this is feasible, 
affordable, cost effective, and does not divert resources 
from vaccinating the primary target population or from 
effective cervical-cancer screening programmes. HPV 
vaccination of  males is not recommended as a priority.19
With regard to vaccination schedule, WHO has changed 
its previous recommendation of  a 3-dose schedule, to a 
2-dose schedule, For both the bivalent and quadrivalent 
HPV vaccines, a 2-dose schedule with a 6-month inter-
val between doses, is recommended for females younger 
than 15 years.19 Those >15 years of  age at the time of  
the second dose are also adequately covered by 2 doses. 
An interval no greater than 12–15 months is suggested, 
in order to complete the schedule promptly – and before 
becoming sexually active. If  the interval between doses 
is shorter than 5 months, a third dose should be given 
at least 6 months after the first dose. A 3-dose schedule 
(0, 1–2, 6 months) is recommended for females aged 15 
years and older, and for those known to be immune-com-
promised and/or HIV-infected (regardless of  whether 
they are receiving antiretroviral therapy).19
Health-care workers (HCW) play a significant role in pa-
rental decisions related to HPV vaccination. Many studies 
report that HCW are the most trusted, preferred and in-
fluential source of  HPV vaccine information for adoles-
cents and parents.20-22 There were mixed results reported 
regarding HCW recommendation of  HPV vaccines – de-
spite its importance. A study reported a 93-fold increase 
of  HPV vaccination uptake because of  HCW discussion 
and recommendation of  HPV vaccination.23 Another 
study amongst physicians in Australia and Asia reported 
that about half  of  them have initiated conversations with 
patients and families about HPV vaccination.21,24
In South Africa, HPV vaccination was recently incorpo-
rated into the school health system. The first dose was 
carried out among grade four learners in April 2014. An-
other pilot study conducted among 39 school learners in 
KwaZulu-Natal province of  South Africa, found that the 
vaccine completion rate was very high as 99.7%, 97.9% 
and 97.8% for the first, second and third doses respec-
tively.25 Doctors’ knowledge and attitudes are very impor-
tant as it influences parents' decisions about vaccine ac-
ceptability. No previous studies in South Africa have been 
conducted among doctors to investigate their knowledge 
and attitudes regarding HPV vaccination. Therefore, this 
study seeks to investigate doctors’ knowledge, attitudes 
and recommendations, regarding HPV vaccination. 
Materials and methods
This was a quantitative cross-sectional study conducted 
among doctors who were employed permanently at the 
Dr George Mukhari Hospital (DGMH). The hospital is 
a referral hospital for Polokwane in the NorthWest Prov-
ince of  South Africa, but is situated about 35 km north 
of  South Africa’s capital city Pretoria, in Gauteng Prov-
ince. Currently there are about 1000 doctors working in 
this hospital which has 39 wards and 1400 beds. Although 
a teaching hospital, it also provides out-patient treatment 
to its catchment population.
The minimum sample size for the study was calculated to 
be 270, this based on the following information: assuming 
50% of  doctors have enough knowledge regarding HPV 
vaccination, with a 95% confidence level and 80% power 
of  the study. For uncompleted questionnaires, 20% more 
were added to the sample size, and thus the final sample 
size was 324 doctors. Sampling techniques, data collec-
tion, and questionnaire developments were well explained 
elsewhere.26 Doctors working in the intensive care unit 
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and laboratory workers were excluded from the study. 
Data collection took place between March and June 2013.
The Medunsa Research Ethics Committee of  the Uni-
versity of  Limpopo and the hospital management team 
approved the study. The research assistant informed all 
participants about the study before they signed the con-
sent form and completed the questionnaire. Their confi-
dentiality and anonymity was maintained at all times.
Demographic variables were summarized using descrip-
tive statistics such as mean (SD) for continuous variables 
and percentages for categorical variables. χ2 -test or Fish-
ers’ exact test was used to compare categorical variables. 
Stepwise binary logistic regression models were carried 
out to determine variables that were significantly associat-
ed with recommending HPV vaccination to the patients. 
P values less than 0.05 were considered to be statistically 
significant.
Results
A total of  325 questionnaires were distributed and 320 
completed questionnaires were received. With regard to 
participants’ socio-demographic information, just over 
half  of  them were younger than 40 years – as the aver-
age age was 39 years with a standard deviation of  8 years. 
Most participants were female (78%) and medical officers 
(87%). About half  of  respondent (47.5%) had more than 
10 years of  working experience and 30.9% were working 
for more than 7 hours a week in an out-patient depart-
ment (see Table 1).
Table 1: Respondents provider and practice characteristics 
 
 Variable Frequency Percent 
Gender     
Female 250 78.1 
Male 70 21.9 
Age group     
less than 30 years 35 10.9 
30 - 39 years 137 42.8 
40 - 49 years 101 31.6 
50 years or above 47 14.7 
Average age (SD) 39.33 years (8.41) 
Profession     
Medical Officer 277 86.6 
Intern 43 13.4 
Years of Experience     
Less than 10 years 168 52.5 
10 - 19 years 114 35.6 
20 years or more 38 11.9 
Mean years of experience (SD) 10.16 years (7.04) 
Hours spending in direct patient care per week     
Less than 7 hours 221 69.1 
7 or more hours 99 30.9 
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With regards to doctors’ knowledge about HPV infection 
and HPV vaccine, all the doctors were aware of  HPV 
and they knew that HPV was transmitted sexually as well 
as HPV infection is the main cause for cervical cancer. 
Table 2 summarises doctors’ knowledge regarding HPV 
infections and the HPV vaccine. More than half  of  the 
doctors (59.4%) did not know that HPV is the most com-
mon sexually transmitted infection. Only 31% doctors 
knew that conventional screening HPV tests have a sen-
sitivity of  >75%. The majority knew that >80% of  the 
population harbours HPV (75.3%) and persistent HPV 
infection is a necessary cause of  cervical cancer (94.7%). 
None of  the doctors knew that a regular Pap test with a 
frequency of  ≤3 years reduces the risk of  cervical cancer 
between 71% and 90% and between 60% to 80% cervical 
cancer is caused by HPV-16 and -18. More than half  of  
the doctors (59.4%) could not name both the vaccines 
and 75.3% did not know the effectiveness of  the vac-
cines. Overall, the knowledge scores were low among the 
doctors as their average score was 5.11 (SD=1.29) out 
of  11 questions where each questions was allocated one 
point for correct answers.
Table 2: Doctors' Knowledge regarding the HPV Infection and HPV Vaccine (n = 320) 
Knowledge (correct answer) I will prescribe the HPV 






HPV is the most common sexually 
transmitted infection 
5 (41.7%)# 128 (41.6%) 133 (41.6%) 0.000 0.994 
>80% of the population is infected 
with HPV at some point in their life 
9 (75.0%) 232 (75.3%) 241 (75.3%) 0.001 0.980 
Persistent HPV infection is a necessary 
cause of cervical cancer 
11 (91.7%) 292 (94.8%) 303 (94.7%) 0.226 0.634 
Conventional screening HPV test have 
a sensitivity of  > 75% 
7 (58.3%) 92 (29.9%) 99 (30.9%) 4.379 0.042 
In South Africa, less than 20% women 
have had a Pap smear test 
12 (100.0%) 278 (90.3%) 290 (90.6%) 1.290 0.256 
There are 13 to 17 HPV types 1 (8.3%) 72 (23.4%) 73 (22.8%) 1.484 0.223 
HPV 6 and 11 are responsible for > 
90% of anogenital warts 
8 (66.7%) 276 (89.6%) 284 (88.8%) 6.090 0.035 
A regular Pap test with a frequency of ≤ 
3 years reduces the lifetime risk of 
cervical 
cancer by 71 – 90% 
0 (0.0) 0 (0.0) 0 (0.0)   
The proportion of cervical 
cancer related to HPV 16 and 18 types 
is: 61 – 80% 
0 (0.0) 0 (0.0) 0 (0.0)   
Quadrivalent and Bivalent are HPV 
vaccines 
5 (41.7%) 128 (41.6%) 133 (41.6%) 0.820 0.936 
The vaccines are very effective 0 (0.0%) 79 (25.6%) 79 (24.7%) 4.747 0.032 
Overall mean (SD) 4.83 (1.40) 5.12 (1.28) 5.11 (1.29) 0.756 0.450* 
*According to t-test., #column percentage 
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Doctors’ attitudes concerning HPV immunization, per-
ceived support, expected benefits and intention to recom-
mend vaccination, are shown in table 3 (below). Only one 
doctor agreed that the vaccines should be given to girls 
before they become sexually active. Less than half  (45%) 
of  the doctors reported that the best age for a universal 
immunization programme would be less than 14 years.
 
All the doctors reported that physicians will recommend 
HPV vaccination. Almost all the participants agreed that 
parents will accept HPV vaccination for their children; 
that adolescents and young adults will accept HPV vac-
cination; that parents will prefer HPV vaccination to be 
given at school; that a vaccination programme will reduce 
the frequency of  screening in vaccinated women, and 
also reduce the number of  post-screening follow-up in-
terventions (>97%).
Table 3. Doctors’ attitudes concerning HPV immunization, perceived support, expected 
benefits, and intention to recommend vaccination (n=320) 
 
Statements (doctors agree with the 
statement) 
I will prescribe the HPV vaccine 







No (n, %) Yes (n, %) 
HPV vaccine should be given           
Before sexually active lifestyles 0 (0.0) 1 (0.3) 1 (0.3) 0.039 0.843 
The best age for an eventual 
immunization programme would be 
<14 years 
8 (66.7) 136 (44.2) 144 (45.0) 2.706 0.439 
A vaccination programme would 
eventually permit 
          
Beginning screening later in life 12 (100.0) 302 (98.1) 314 (98.1) 0.238 0.625 
Reduction of the frequency of 
screening interventions in 
vaccinated females 
12 (100.0) 300 (97.4) 312 (97.5) 0.320 0.572 
Reduction of the number of post-
screening 
12 (100.0) 299 (97.1) 311 (97.2) 0.361 0.548 
The abolishment of screening 12 (100.0) 289 (93.8) 301 (94.1) 0.787 0.375 
In your opinion most           
Physicians will recommend HPV 
vaccination to their patients 
12 (100.0) 308 (100.0) 320 (100.0)     
Parents will accept HPV vaccination 
for their children <14 years of age 
12 (100.0) 301 (97.7) 313 (97.8) 0.279 0.597 
Parents will prefer HPV vaccination 
to be given at school 
12 (100.0) 302 (98.1) 314 (98.1) 0.238 0.625 
Adolescents and young adults will 
accept HPV vaccination 
12 (100.0) 307 (99.7) 319 (99.7) 0.039 0.843 
Adolescents and young adults will 
seek HPV vaccination 
12 (100.0) 304 (98.7) 316 (98.8) 0.158 0.691 
Your patients will comply with 
counsel regarding 
          
Safe sexual behaviour 0 (0.0) 7 (2.3) 7 (2.2) 0.279 0.597 
Regular screening for cervical 
cancer 
1 (8.3) 21 (6.8) 22 (6.9) 0.041 0.893 
HPV vaccination 8 (66.7) 271 (88.0) 279 (87.2) 4.700 0.030 
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Overall, most (96.3%) of  the doctors mentioned that 
they will recommend the vaccines to their patients. Fac-
tors that contribute in terms of  recommending HPV vac-
cination are shown in Table 4 (below). Backward stepwise 
binary logistic regression analysis was carried out to find 
the significant predictor for recommending HPV vacci-
nation to the patients. Initially all those variables that were 
significantly associated with prescribing HPV vaccination 
to the patient were included in the model. The Hosmer 
and Lemeshow test indicated that the model fitted ade-
quately (Chi-square = 4.159, p=0.385). The classification 
table showed that overall the model predicted 96.3% ac-
curately. The results showed that doctors who mentioned 
that HPV 6 and 11 are responsible, comply with HPV 
vaccination, and information received about HPV vac-
cination – were 5.677, 4.907 or 4.458 times, respectively, 
more likely to recommend HPV vaccination to their pa-
tients compared to their counterparts (p<0.05).
Discussion
This is the first quantitative study conducted among medi-
cal doctors in South Africa to investigate their knowledge, 
attitudes and recommendations about HPV vaccination 
to their patients. Overall, the level of  knowledge regard-
ing HPV infections and vaccination among the medical 
doctors was low, but the HPV vaccine recommendation 
was very high. All the doctors in the study were aware of  
HPV, and they knew HPV was transmitted sexually and 
that HPV infection causes cervical cancer. Many of  the 
respondents did not know that HPV is the most com-
mon sexually transmitted infection and that the conven-
tional screening HPV test has a sensitivity of  >75%. It 
was surprising that none of  the doctors knew that the 
regular Pap smear test reduces the risk of  cervical cancer 
by 71% to 90% and that 60% to 80% of  cervical cancer 
is caused by HPV-16 and -18. More than half  of  the doc-
tors could not name both the vaccines, and 75.3% did 
Table 4: Backward stepwise binary logistic regression output for recommending HPV 









Step 1a Conventional screening of HPV test .294 .085 1.011 .052 
HPV 6 and 11 are responsible 5.413 1.338 21.906 .018 
Comply with HPV vaccination 4.784 1.193 19.180 .027 
Information received so far about HPV 
vaccination 
4.130 1.082 15.767 .038 
Time spent in direct patient care per week .802 .215 2.992 .742 
Constant 1.303     .820 
Step 2a Conventional screening of HPV test .290 .084 .998 .050 
HPV 6 and 11 are responsible 5.677 1.439 22.395 .013 
Comply with HPV vaccination 4.907 1.233 19.523 .024 
Information received so far about HPV 
vaccination 
4.458 1.262 15.750 .020 
Constant 1.078     .941 
 
a. Variable(s) entered on step 1: Conventional screening of HPV test; HPV 6 and 11 are responsible; Comply with 
HPV vaccination; Information received so far about HPV vaccination; Time spent in direct patient care per week. 
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not know the effectiveness of  the vaccines. With regard 
to knowledge about HPV infections and vaccines, studies 
have reported various levels of  knowledge among physi-
cians. For example, a recent study conducted among pe-
diatricians in Serbia, reported insufficient knowledge of  
HPV infection and the HPV vaccine.27 A Jordanian study 
assessed the knowledge and attitudes of  obstetricians 
and gynecologists towards HPV infection and its vaccine, 
and found that the vast majority knew about most of  the 
facts relating to HPV infection.28 Among Nigerian HCW, 
91% were aware of  HPV – but only 44.0% were aware of  
the HPV vaccine.29 A Cross-Sectional Study conducted 
among Primary Care Physicians in Hong Kong found a 
low level of  knowledge with regard to the epidemiology 
of  HPV infection.30
 
HCW recommendations have a significant impact on 
the acceptability of  the vaccines – as they are the most 
trusted people. With regard to recommending HPV vac-
cines, all the doctors agreed to recommend the vaccines 
to their patients. This finding is consistent with a national 
survey of  pediatricians and family practice physicians in 
the USA, which found that 98% of  pediatricians and 88% 
of  family practice physicians reported offering HPV vac-
cine to their female patients.31 Another study from the 
USA reported about 33% of  physicians offering the HPV 
vaccine routinely to their eligible patients.32 Investigations 
of  the awareness and attitudes about the HPV vaccines 
among pediatricians, obstetricians and gynecologists in 
Turkey, showed that HPV vaccines were recommended by 
59.4%, 82.6%, 66.7% and 80.6% of  pediatricians, OBG 
specialists, OBG residents and pediatric residents, respec-
tively.33 High acceptability of  the HPV vaccine was found 
among French general practitioners and the acceptability 
rate increased from 79.9% to 87.1% between the years 
2007 and 2010.34 Other studies have also reported similar 
findings among health-care workers.31,35-37
 
The present study showed that all the doctors – except 
one – disapproved of  giving the vaccine before becom-
ing sexually active. This finding is very discouraging, as 
doctors are the main driver for the high uptake of  HPV 
vaccination among adolescents. This is in contrast with 
other studies conducted elsewhere. Most Jordanian ob-
stetricians and gynecologists (78%) indicated that the 
vaccine should be given to girls before they became sexu-
ally active.28 But 39% of  Asian physicians did not approve 
HPV vaccination to girls before the onset of  sexual activ-
ity.21 Our study was conducted before the implementation 
of  HPV vaccination nationally through the school health 
system in the year 2014. Doctors’ knowledge about vac-
cine safety and efficacy was low in this study. 
 
The recommended HPV vaccination age varies consider-
ably throughout the world among HCW. Doctors in this 
study were asked to indicate the best age for vaccination. 
Less than half  indicated that <14 years was the best time 
for HPV vaccination. This finding is similar to a study 
among primary care physicians in Hong Kong (45.6%).30 
An American study highlighted that most pediatricians 
recommended HPV vaccines to girls aged 16 to 18 years, 
while another study indicated that fewer physicians and 
pediatricians recommended HPV vaccines for children 
aged 11 to 12 years than for older female adolescents.31,38 
Another study conducted in England found that doctors’ 
recommendation to vaccinate increased as the age of  the 
vaccination increases.39 This might have a significantly 
negative impact on vaccination coverage nationally.
 
This study had some limitations. First, it was a cross-
sectional study. Therefore a causal relationship could not 
establish a relationship between doctors’ knowledge or 
attitudes and their HPV prescriptions. This study was 
conducted in one institution, and thus generalisation of  
results is not possible. The self-reported data is subject 
to bias, but anonymity of  the questionnaire may have mi-
nimised this. This study has revealed doctors’ knowledge 
and attitudes regarding HPV infections and HPV vacci-
nation. The findings should motivate further studies and 
they will be helpful for programme and policy develop-
ment on HPV immunisation and the prevention of  cervi-
cal cancer in South Africa.
 
Conclusion
South African doctors’ overall knowledge of  HPV infec-
tion and vaccines was poor, but there was very high ac-
ceptability to recommend the vaccine to their patients. 
Doctors who knew that HPV 6 and 11 are responsible 
for > 90% of  anogenital warts, whose patients comply 
with the counseling regarding HPV vaccination, and who 
received sufficient information about HPV vaccination 
– were more likely to recommend HPV vaccination to 
their patients. There is a need for health education on 
safety and efficacy and the best time for HPV vaccination 
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among the doctors and the general public, in order to 
reduce the burden of  cervical cancer and to enhance the 
benefit of  this preventative tool.
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